Close
Blog & Resources Camargo Blog April 20th, 2010

505(b)(2): Repositioning, Repurposing or What?

Last week I made a presentation at the Society of Biomolecular Sciences (SBS) 2010 Annual Meeting in Phoenix (due to the Iceland volcano eruption, many participants are still there). The occasion was the inaugural meeting of the newly formed Special Interest Group for Repositioning Drugs (see the announcement of this new SIG). Dr. Chris Lipinsky was also on the agenda. Chris is a consultant to Melior Discovery and he is widely viewed to be a founding father of drug repositioning while at Pfizer. He and I have appeared at previous conferences on drug repositioning sponsored in part by Melior and Camargo. Judging from the name of the organization, and looking at Chris’ background, you might ask why was Camargo and Ken Phelps asked to present.

After all, the subject of SBS is, in large part, about using screening techniques to aid drug discovery. Repositioning, as defined by Chris and others is the process of examining alternate indications for drugs that have failed in the clinic. We have also heard that repurposing (with or without the hyphen; re-purposing) is interchangeable with repositioning. When many people think of repositioning drugs they expect the outcome to be new IP and a full NDA. Pharma does repositioning as a way to salvage a drug that was in its pipeline. But as Chris pointed out in his fine talk, repositioning in pharma can also be used to extend the life of an approved drug. This is where I came in.

Camargo specializes in helping its clients make changes to drug products that are already on the market. Since there is often publicly available pre-clinical and clinical information to support the existing product and the proposed changes, Camargo uses the 505(b)(2) regulatory pathway to gain approval. The changes we make are also very much applicable to pharma ‘repositioning’. I cited a couple of examples:

It is well established that the efficacy of many existing drugs are less than optimal. In fact, new drugs often fail in phase 3 because they don’t show superiority to placebo. The following figure shows that, for many classes of drugs, less than 50% of patients find them effective.

patient_response-chart1

Why aren’t a greater percentage of currently marketed more effective ? While there are many reasons, sometimes it is the dose, site of administration or formulation. Many of these drugs can be improved – “repositioned” by making the required changes.

For many drugs, lack of efficacy may also be related to the time of dose as shown in the following slide.

patient_response20

To address the timing of a dose, it may be possible to design an appropriate formulation.

At SBS, I used the example of prodrugs. Prodrugs are modifications of new or existing drugs to improve efficacy or safety. Prodrugs can be developed to improve bioavailability, for example, to change an IV to oral administration. Oral delivery may reduce side effects and allow higher doses.

In summary, drug repositioning or repurposing can be performed on both pipeline and currently marketed drugs. 505(b)(2) can be used to gain approval of the repositioned or repurposed marketed drugs.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights